Daily Cardiology Research Analysis
Analyzed 50 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today: a meta-analysis consolidates the benefits of SGLT2 inhibitors in heart failure with mildly reduced or preserved ejection fraction; a 15,550-patient international cohort ranks acute kidney injury as the top contributor to early post–cardiac surgery mortality; and a multi-omics Mendelian randomization study suggests that therapeutic sclerostin inhibition may increase atrial fibrillation risk despite improving bone density.
Research Themes
- Heart failure therapeutics in HFmrEF/HFpEF
- Perioperative risk and preventable complications after cardiac surgery
- Genetic/mechanistic safety signals affecting cardiovascular outcomes
Selected Articles
1. Proxied therapeutic inhibition on sclerostin and atrial fibrillation risk.
Using multi-omics Mendelian randomization anchored by B4GALNT3 trans-pQTLs that lower circulating sclerostin, the study found that genetically proxied sclerostin inhibition increases estimated bone mineral density while raising atrial fibrillation risk. In vitro B4GALNT3 overexpression reduced SOST secretion, triangulating the causal pathway.
Impact: This is among the first multi-omics studies to link reduced sclerostin to atrial fibrillation risk using genetic instruments and experimental validation, directly informing cardiovascular safety of SOST-inhibiting osteoporosis therapies.
Clinical Implications: Clinicians should monitor for atrial fibrillation in patients receiving sclerostin inhibitors (e.g., with periodic ECG and symptom checks), particularly in those with baseline arrhythmia risk. Shared decision-making should weigh bone benefits against potential AF risk.
Key Findings
- Polygenic overlap was observed between circulating SOST, heel eBMD, and atrial fibrillation.
- B4GALNT3 trans-pQTLs served as valid instruments: higher B4GALNT3 expression associated with lower SOST, higher eBMD, and higher AF risk.
- In vitro B4GALNT3 overexpression significantly decreased SOST protein secretion, supporting the causal pathway.
- Genetically proxied SOST inhibition increased eBMD (β≈0.034) and was associated with increased AF risk in MR analyses.
Methodological Strengths
- Triangulation across genetics, transcriptomics, proteomics, and in vitro functional assays
- Large-scale GWAS datasets (hundreds of thousands to over one million participants) with external validation
Limitations
- Mendelian randomization relies on assumptions (e.g., no horizontal pleiotropy), and trans-pQTLs may introduce residual pleiotropy
- Population ancestry and phenotype definitions in GWAS may limit generalizability; clinical outcome validation is needed
Future Directions: Prospective pharmacovigilance and randomized safety studies should quantify AF incidence under sclerostin inhibitors and identify high-risk subgroups and mitigating strategies.
BACKGROUND: Pharmacological inhibition of sclerostin (SOST) is clinically applied to treat osteoporosis. However, large-scale randomized controlled trials have reported conflicting findings regarding the cardiovascular effects of SOST inhibition. This study aimed to evaluate whether sustained SOST inhibition, mimicked by instrumental genetic variants, is associated with the altered risk of cardiovascular diseases (CVDs). METHODS: The individual-level genomic data were obtained from the UK Biobank, including 377,585 p
2. Efficacy of SGLT2 Inhibitors in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: An Updated Systematic Review and Meta-Analysis.
In 18 randomized trials including 18,774 patients with LVEF >40%, SGLT2 inhibitors reduced the composite of cardiovascular death or first HF hospitalization and improved patient-reported (KCCQ) and functional (6MWD) outcomes. Mortality-specific effects remain uncertain and warrant further study.
Impact: This meta-analysis consolidates the role of SGLT2 inhibitors as foundational therapy in HFmrEF/HFpEF, extending benefits beyond HFrEF and supporting guideline evolution.
Clinical Implications: Consider initiating SGLT2 inhibitors across the LVEF >40% HF spectrum to reduce HF hospitalizations and improve quality of life, irrespective of diabetes status, while recognizing that mortality benefits are not yet fully defined.
Key Findings
- Included 18 RCTs with 18,774 patients (9,564 SGLT2 inhibitors; 9,210 control) with LVEF >40%.
- SGLT2 inhibitors significantly reduced the primary composite endpoint of CV death or first HF hospitalization (reported OR 0.71; 95% CI 0.66-0.75).
- Improvements were observed in KCCQ scores and 6-minute walk distance, indicating better functional status and quality of life.
- Independent effects on mortality endpoints remain to be clarified.
Methodological Strengths
- Synthesis of randomized controlled trials with large aggregate sample size
- Evaluation of both hard clinical endpoints and patient-centered functional outcomes
Limitations
- Heterogeneity in trial populations and follow-up may influence pooled estimates
- Mortality-specific effects were not definitively established in the aggregate data
Future Directions: Individual participant data meta-analyses and longer-term outcome trials are needed to clarify mortality effects and optimal patient selection.
BACKGROUND: Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) constitute a substantial clinical burden with limited therapeutic options. While sodium-glucose cotransporter 2 (SGLT2) inhibitors are established therapies for heart failure with reduced ejection fraction, their efficacy and safety profile in HFmrEF and HFpEF warrant comprehensive synthesis. OBJECTIVE: To systematically evaluate the impact of SGLT2 inhibitors on cardiov
3. Association between complications and mortality after cardiac surgery: Results from the VISION Cardiac Surgery prospective cohort study.
In a 15,550-patient, 12-country prospective cardiac surgery cohort, 30-day mortality was 3.0% and 1-year cumulative mortality 5.5%. Acute kidney injury contributed the largest share of early mortality (PAF 37%), followed by bleeding (12%), infection (12%), and myocardial injury (10%), highlighting key targets for prevention.
Impact: This large, multinational prospective analysis quantifies which complications drive early mortality, providing a pragmatic roadmap for targeted quality-improvement initiatives in cardiac surgery.
Clinical Implications: Prioritize prevention and early management of acute kidney injury (e.g., renal-protective strategies), alongside rigorous bleeding and infection control, and monitoring for myocardial injury to reduce early postoperative mortality.
Key Findings
- Among 15,550 cardiac surgery patients, 30-day mortality was 3.0% and 1-year cumulative mortality 5.5%.
- Acute kidney injury occurred in 16.8% (aHR 4.47) with a population attributable fraction (PAF) of 37% for 30-day mortality.
- Bleeding (9.6%; aHR 2.39; PAF 12%), infection (14.5%; aHR 1.95; PAF 12%), and myocardial injury after cardiac surgery (10.8%; aHR 2.01; PAF 10%) were major contributors.
- Targeted prevention of these complications has potential to substantially reduce early postoperative deaths.
Methodological Strengths
- Large, multinational, prospective cohort with standardized outcome assessment
- Use of population attributable fractions to rank complication impact on mortality
Limitations
- Observational design limits causal inference and is subject to residual confounding
- PAF estimates assume accurate measurement and may vary across practice settings
Future Directions: Implement and test kidney-protective bundles and bleeding/infection prevention pathways in pragmatic trials to reduce early mortality post–cardiac surgery.
OBJECTIVES: The most prognostically important complications after cardiac surgery to target for prevention remain uncertain. We aimed to assess the relationship between postoperative complications and mortality at 30 days and 1 year after cardiac surgery and rank the complications by their contribution to mortality. METHODS: We completed an analysis of 15,550 patients from the Vascular Events in Surgery Patients Cohort Evaluation (VISION) Cardiac Surgery prospective cohort study, which enrolled 15,9